The Effect of Sevoflurane and Desflurane Anesthetic Agents Used in Elective Cholecystectomy Surgery on Heme Oxygenase-1 mRNA Expression and Heme Oxygenase-1 Protein Levels: A Comparative Prospective Study

General anesthesia is routinely administered to patients who undergo elective cholecystectomy. The most commonly used inhalation agents during general anesthesia are sevoflurane and desflurane. Participants who will undergo elective cholecystectomy surgery and meet the eligibility criteria will be randomized. Participants will be divided into two groups. One group will receive sevoflurane, and the other group will receive desflurane. Preoperative and postoperative blood samples will be taken from the participants. After the sample collection process is completed, the ELISA method will be used for measuring blood heme oxygenase-1 protein levels, and the PCR technique will be used for measuring blood heme oxygenase-1 mRNA gene expression. The increase in amounts between the two groups will be compared. This study aims to demonstrate the effects of the most commonly used inhalation agents on the levels of heme oxygenase-1 enzyme, which has been shown to be an important enzyme in cellular protection mechanisms, as well as on mRNA gene expression, and to determine which agent may be more effective in preventing cellular damage at the molecular level.

开始日期2024-08-01

申办/合作机构-

NCT06252207 / Not yet recruitingN/A

Desflurane Versus Isoflurane for Speeding Postanesthetic Recovery and Hospital Discharge: a Cluster Randomized Crossover Trial

The investigators thus propose a comparative effectiveness quality improvement project to evaluate the feasibility of switching from near-exclusive use of isoflurane in adult general surgical patients to Desflurane.

开始日期2024-07-01

申办/合作机构

The Cleveland Clinic Foundation

CTRI/2024/05/067486 / Not yet recruiting临床4期

Effect of end tidal carbon dioxide value on the minimum alveolar concentration of desflurane that blunts the adrenergic response to surgical incision:A prospective, Randomized,double blinded trial - Nil

开始日期2024-05-31

申办/合作机构-

100 项与地氟烷相关的临床结果

登录后查看更多信息

100 项与地氟烷相关的转化医学

登录后查看更多信息

100 项与地氟烷相关的专利（医药）

登录后查看更多信息

2,532

项与地氟烷相关的文献（医药）

2024-05-01·Journal of clinical anesthesia

Differential effects of sevoflurane and desflurane on frontal intraoperative electroencephalogram dynamics associated with postoperative delirium

Article

作者: Park, Sujung ; Kim, Jeongmin ; Shin, Dong Ah ; Koo, Bon-Nyeo ; Kim, Keung Nyun ; Kim, Yeon-Su ; Kim, Seong-Eun ; Ha, Yoon ; Kuh, Sung Uk ; Yi, Seong ; Lee, Chang Kyu

STUDY OBJECTIVE:

Intraoperative electroencephalogram (EEG) patterns associated with postoperative delirium (POD) development have been studied, but the differences in EEG recordings between sevoflurane- and desflurane-induced anesthesia have not been clarified. We aimed to distinguish the EEG characteristics of sevoflurane and desflurane in relation to POD development.

DESIGN AND PATIENTS:

We collected frontal four-channel EEG data during the maintenance of anesthesia from 148 elderly patients who received sevoflurane (n = 77) or desflurane (n = 71); 30 patients were diagnosed with delirium postoperatively. The patients were divided into four subgroups based on anesthetics and delirium status: sevoflurane delirium (n = 17), sevoflurane non-delirium (n = 60), desflurane delirium (n = 13), and desflurane non-delirium (n = 58). We compared spectral power, coherence, and pairwise phase consistency (PPC) between sevoflurane and desflurane, and between non-delirium and delirium groups for each anesthetic.

MAIN RESULTS:

In patients without POD, the sevoflurane non-delirium group exhibited higher EEG spectral power across 8.5-35 Hz (99.5% CI bootstrap analysis) and higher PPC from alpha to gamma bands (p < 0.005) compared to the desflurane non-delirium group. Conversely, in patients with POD, no significant EEG differences were observed between the sevoflurane and desflurane delirium groups. For the sevoflurane-induced patients, the sevoflurane delirium group had significantly lower power within 7.5-31.5 Hz (99.5% CI bootstrap analysis), reduced coherence over 8.9-23.8 Hz (99.5% CI bootstrap analysis), and lower PPC values in the alpha band (p < 0.005) compared with the sevoflurane non-delirium group. For the desflurane-induced patients, there were no significant differences in the EEG patterns between delirium and non-delirium groups.

CONCLUSIONS:

In normal patients without POD, sevoflurane demonstrates a higher power spectrum and prefrontal connectivity than desflurane. Furthermore, reduced frontal alpha power, coherence, and connectivity of intraoperative EEG could be associated with an increased risk of POD. These intraoperative EEG characteristics associated with POD are more noticeable in sevoflurane-induced anesthesia than in desflurane-induced anesthesia.

2024-05-01·Current drug delivery

Comparing Recovery from Desflurane and Sevoflurane in Patients with Different Body Fat Percentages: A Randomized Controlled Trial

作者: Cao, Silu ; Wang, Huijuan ; Tang, Lijun ; An, Guanghui

Introduction::

Increased body fat may influence the partition coefficients of inhaled anesthetics. We compared patient responses to desflurane and sevoflurane anesthesia, as measured by a quicker recovery and fewer complications, in patients with higher body fat percentages, not only obese people.

Methods::

This study included 120 patients. Participants were stratified into low or high body fat percentages groups using bioelectrical impedance analysis and were randomized 1:1 to receive desflurane or sevoflurane as an inhaled anesthetic, recorded as Low-Desflurane, Low-Sevoflurane, High- Desflurane, and High-Sevoflurane. Recovery time, Riker sedation–agitation scale scores, and complications were recorded over 1 hour in the post-anesthesia care unit.

Results::

A total of 106 patients were analyzed. There were no significant differences in the overall recovery time between the patient subgroups with higher and lower body fat percentages; in addition, there were no significant differences in the incidence of nausea, vomiting,dizziness, or headache (all p>0.05). However, the incidence of agitation emergence in the HighSevoflurane subgroup was significantly higher compared to the High-Desflurane subgroup (33.3% vs.7.41%; p = 0.043).

Conclusion::

In conclusion, for patients with a lower body fat percentage, both desflurane and sevoflurane can provide good and fast recovery; for patients with a higher body fat percentage,desflurane may provide better recovery with a lower incidence of agitation emergence compared to sevoflurane.

2024-03-01·BJA open

A randomised controlled trial comparing quality of recovery between desflurane and isoflurane inhalation anaesthesia in patients undergoing ophthalmological surgery at a tertiary hospital in South Africa (DIQoR trial)

Article

作者: Steyl, Charlé ; Kluyts, Hyla-Louise

Background:

The patient's experience of their postoperative recovery is an important perioperative outcome, with the 15-item quality of recovery scale (QoR-15) recommended as a standardised outcomes measure. Desflurane has a faster emergence from anaesthesia compared with other volatile anaesthetics, but it is uncertain whether this translates to better subjective quality of recovery. The hypothesis for this study is that patients receiving desflurane for maintenance of anaesthesia would have better postoperative quality of recovery than patients receiving isoflurane.

Methods:

Male and female adult patients undergoing ophthalmological surgery under general anaesthesia were randomly allocated to receive desflurane or isoflurane for maintenance of anaesthesia. The primary outcome was to compare postoperative QoR-15 scores. Secondary outcomes included comparing preoperative QoR-15 scores, volatile agent consumption, and time spent in the recovery room.

Results:

Data from 164 patients were analysed (80 desflurane, 84 isoflurane). Median (Q1, Q3) postoperative QoR-15 scores were not significantly different (desflurane: 145 [141, 148], isoflurane: 144 [139, 147], 95% confidence interval 0-3, P=0.176, minimal clinically important difference=8). Median (Q1, Q3) volatile agent consumption was 15.4 (12.5, 19.3) ml hr^-1 in the desflurane group, and 7.4 (5.9, 9.7) ml hr^-1 in the isoflurane group. Median (Q1, Q3) time spent in the recovery room was significantly shorter in the desflurane group (desflurane: 18 [13, 23]; isoflurane: 25 [19, 32], 95% confidence interval -10 to 5, P<0.001).

Conclusions:

This study found no difference in quality of recovery between patients who received desflurane or isoflurane for maintenance of general anaesthesia during ophthalmological surgery. A shorter time in the recovery room was not associated with improved QoR-15 scores.

Clinical trial registration:

NCT04188314.

项与地氟烷相关的新闻（医药）

2024-06-11

·米内网

恒瑞发威了！独家品种暴涨506%，150款1类新药、9大首仿冲刺，27款新药上市可期

精彩内容近日，恒瑞医药创新药研发进展不断：SHR-A1811(Her2 ADC)纳入突破性疗法，氟唑帕利新适应症获批，SHR-4849、SHR-9539、HRS-5346等首次在国内获批临床......目前公司有23款创新药在国内获批，2023年创新药收入首破百亿；178款新药（150款1类新药）处于申请临床及以上阶段，其中27款已报产或步入III期临床，上市可期；2019年至今拿下19个首仿，10个新品在路上。近年来公司海外BD动作不断，17个创新药的临床试验顺利推进中。创新药收入首破百亿！150款1类新药霸屏受集采和医保降价影响，2021、2022年恒瑞医药陷入营收、净利双降的窘境。但在集采影响逐渐出清及创新药加持下，2023年公司业绩实现止跌回升，并将上升势头延续到了2024年一季度。 4月17日晚间，恒瑞医药发布2023年年报及2024年一季度报。2023年公司实现营业收入228.20亿元，同比增长7.26%；归母净利润43.02亿元，同比增长10.14%。2024年一季度，公司实现营收59.98亿元，同比增长9.2%；归母净利润13.69亿元，同比增长10.48%。在经历集采的阵痛后，创新药已然成为恒瑞医药的重心，并逐渐成为其业绩增长的主要推动力。2023年公司创新药收入达106.37亿元（含税，不含对外许可收入），虽然面临外部环境变化、产品降价及准入难等因素影响，仍然实现了22.1%的同比增长，占营收比重达到46.6%。截至目前，恒瑞医药已在国内获批上市14款自研创新药（13款1类新药）、2款合作引进创新药、6款2类改良型新药及1款生物类似药，涉及抗肿瘤、麻醉镇痛、消化代谢、抗感染等多个治疗领域，创新成果稳居行业领先地位。得益于国家医保助力及出色的商业化能力，恒瑞医药近年来获批上市的新药放量明显，如2021年6月获批的海曲泊帕乙醇胺，2023年在中国三大终端六大市场（统计范围详见本文末）终端的销售额超过12亿元，同比增长约104%；同样于2021年6月获批的贝伐珠单抗注射液是恒瑞医药首款生物类似药，2023年销售额突破6亿元，同比增长约102%；2021年底获批的达尔西利，2023年销售额超过2亿元，同比增长约506%；2022年6月获批的瑞维鲁胺，2023年销售额超过2亿元。为保证创新成果产出，恒瑞医药持续加大创新力度。2023年公司研发投入61.50亿元，近十年来（2014-2023）累计研发投入接近350亿元。米内网数据显示，含合作引进的新药在内，目前恒瑞医药在国内有178款新药（不含已有批文、撤回或不批准品种）处于申请临床及以上阶段，其中有150款为1类新药。恒瑞医药国内在研新药来源：米内网综合数据库从研发进度看，27款新药（20款1类新药）处于NDA或III期临床阶段（不含II/III期临床），上市可期；从治疗类别看，处于获批临床及以上阶段的173款新药涵盖13个治疗大类，集中在抗肿瘤和免疫调节剂、消化系统及代谢药、神经系统药物三大领域。 ADC为恒瑞医药在抗肿瘤领域最为重要的布局，目前公司已有11个新型、具有差异化的ADC分子成功获批临床，其中注射用SHR-A1811（Her2 ADC）、注射用SHR-A1921（Trop2 ADC）已步入III期临床，注射用SHR-A1904（Claudin18.2 ADC）处于Ib/III期临床，注射用SHR-A2009（HER3 ADC）、注射用SHR-A1912（CD79b ADC）、注射用SHR-A2102（Nectin-4 ADC）等处于I/II期临床。针对热门的CLP-1靶点，恒瑞医药已有6款相关产品获批临床，其中长效胰岛素+GLP-1类似物HR17031注射液（2型糖尿病）、GIP/GLP-1双重激动剂HRS9531注射液（减重）已步入III期临床；GLP-1受体激动剂诺利糖肽注射液（2型糖尿病/肥胖）、口服GLP-1受体激动剂HRS-7535片（2型糖尿病/肥胖）正在开展II期临床；GLP-1/GCGR双重激动剂SHR-1816注射液（糖尿病）、口服GLP-1/GIP双受体激动剂HRS9531片（超重或肥胖/2型糖尿病）处于I期临床。拿下19个首仿！10个新品在路上除了不断加码创新药，恒瑞医药在仿制药亦有布局，重点关注首仿、高端剂型等。据不完全统计，2019年以来，公司有19个首仿（含剂型首仿）在国内获批生产并视同过评，其中注射用塞替派、环磷酰胺胶囊、布比卡因脂质体注射液、昂丹司琼口腔溶解薄膜、盐酸艾司氯胺酮注射液至今仍为独家品种，10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)注射液至今仍为国产独家品种。 2019年以来恒瑞医药获批上市的首仿来源：米内网中国申报进度（MED）数据库截至目前，恒瑞医药有65个品种过评/视同过评，其中36个为国内首家，注射用塞替派、布比卡因脂质体注射液、10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)注射液、美司钠注射液、环磷酰胺胶囊、碘化油注射液(罂粟乙碘油注射液)、昂丹司琼口腔溶解薄膜、注射用环磷酰胺、盐酸艾司氯胺酮注射液、吸入用地氟烷等为独家过评。恒瑞医药已过评品种中，共有30余个品种被纳入国采，其中有24个品种中标。公司多个核心仿制药已被纳入集采，集采影响将逐步出清。米内网数据显示，2023年中国公立医疗机构终端恒瑞医药销售额超10亿元的仿制药中，1个已被纳入集采，2个未被纳入集采且暂不满足初步条件，1个未被纳入集采且满足初步入围条件。除去已获批/撤回或不批准品种，目前恒瑞医药还有10个新分类申报品种在审，其中9个品种暂无首仿（含剂型首仿）获批，剩下1个品种仅有1家国产企业及原研厂家拥有生产批文。恒瑞医药新分类申报且在审品种来源：米内网中国申报进度（MED）数据库镓[68Ga]伊索曲肽注射液、镥[177Lu]氧奥曲肽注射液是恒瑞医药在核药领域布局的首对放射性精准诊疗产品；艾氟洛芬贴剂是公司首款以新注册分类申报的贴膏剂产品；ω-3鱼油中长链脂肪乳/氨基酸(16)/葡萄糖(30%)注射液为肠外营养三腔袋，复方氨基酸(16AA)/葡萄糖(12.6%)电解质注射液为肠外营养双室袋。探索出海新模式，国际化进程持续推进 5月16日晚，恒瑞医药公告称，将具有自主知识产权的GLP-1组合创新药HRS-7535、HRS9531、HRS-4729在除大中华区以外的全球范围内开发、生产和商业化的独家权利有偿许可给美国Hercules公司。根据协议，恒瑞医药将获得1.1亿美元的首付款和近期里程碑款，累计不超过2亿美元的临床开发及监管里程碑款，累计不超过57.25亿美元的销售里程碑款。作为对外许可交易对价的一部分，恒瑞医药还将取得美国Hercules公司19.9%的股权，成为Hercules的股东之一。据悉，这种交易模式在海外MNC中不乏先例，但在国内确实是比较新的探索。作为国内创新药出海的活跃分子，恒瑞医药近两年来BD动作不断：2023年，从SHR2554（EZH2抑制剂）开启首章，到与Merck达成最高可达14亿欧元的交易，一年时间共达成5起海外BD授权，交易总额超40亿美元。值得一提的是，与Merck的合作是恒瑞医药首次与全球大型跨国企业牵手；2024年，开篇即王炸，不仅达成超60亿美元的合作（超过2023年全年交易总额），还入股了Hercules，探索出海新模式。 2023年以来恒瑞医药部分license-out项目来源：公司公告，米内网整理国际化是恒瑞医药多年来坚持的战略方针，公司坚持自主研发与开放合作并重，在内生发展的基础上加强国际合作，已从最初的仿制药出口逐步走向“仿制药+创新药”出口的并行阶段。通过与多家药企合作，恒瑞医药将卡瑞利珠单抗、吡咯替尼、SHR2554、SHR-1701、SHR-1905、SHR0302、SHR-A1904、HRS-1167、HRS-7535、HRS9531、HRS-4729等多款具有自主知识产权的创新药对外授权。在自主研发上，近几年来，恒瑞医药有多个仿制药的ANDA申请获得美国FDA批准，包括他克莫司缓释胶囊、钆布醇注射液、碘克沙醇注射液、钆特酸葡胺注射液等，其中他克莫司缓释胶囊为中美双首仿。此外，截至2024年3月31日，恒瑞医药已在海外布局了17个创新药，其中PD-1单抗卡瑞利珠单抗（联合阿帕替尼一线治疗晚期肝细胞癌）已向FDA递交新药上市申请（BLA），SHR0302、吡咯替尼、氟唑帕利、海曲泊帕乙醇胺等均处于III期临床阶段。恒瑞医药海外创新药临床进展（截至2024年3月31日）资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至6月7日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

财报临床3期上市批准生物类似药突破性疗法

2024-04-02

·PRNewswire

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

World's leading provider of veterinary care will be first to introduce innovative in-clinic solution to support sustainability goals BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. During a typical anaesthetic procedure, less than five percent of the volatile anaesthetic agent delivered to a patient is absorbed and metabolised, leaving approximately 95 percent it to be exhaled. Continue Reading Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions SageTech's trusted gas-capture technology—which is currently used in human healthcare—works by capturing the waste anaesthetic agent breathed out during an operation by safely adsorbing it into a specially developed reusable capture canister. These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere. "As a leading provider of veterinary care, we have a responsibility to take climate action at scale and lead the way toward more sustainable practices," said Ellie West, RCVS and EBVS® European Specialist in Veterinary Anaesthesia and Analgesia, and Linnaeus Environmental Sustainability Lead. "Our innovative collaboration should help us take a significant step forward in our sustainability journey, aimed at contributing to a better future for the planet—and the people and pets who depend on it." A veterinary-industry first, Mars Veterinary Health's one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts. Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come. "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical. "It has been wonderful to work with the Linnaeus and Waltham teams, and we are confident this pilot project will demonstrate to the veterinary profession how such collaborations can be a collective force for good." This industry-first pilot in sustainable veterinary care is consistent with Mars, Incorporated's Net Zero Roadmap, a detailed action plan for achieving net zero greenhouse gas emissions by 2050, as well as details on the company's progress and history of working on climate action. Details about Mars, Incorporated's wider sustainability—including climate—work can be found in its Sustainable in a Generation Scorecard. About Mars Veterinary Health Mars Veterinary Health is a global division of Mars Petcare dedicated to delivering high-quality pet healthcare to further its collective Purpose: A BETTER WORLD FOR PETS™. Mars Veterinary Health's 70,000 Associates across 3,000 global veterinary clinics put pets, people, and the planet first. The Mars Veterinary Health family includes Associates at AniCura, Banfield, BluePearl, Creature Comforts, Gentle Oak, Hillside, Linnaeus, Mount Pleasant, Tai Wai, VCA, VES, and VSH who demonstrate compassion and expertise while enabling 35 million pet visits each year. Learn more at marsveterinary.com. About Linnaeus Part of Mars Veterinary Health, Linnaeus is a highly respected community of more than 50 primary care and 17 referral veterinary practices based in the UK. Linnaeus employs over 6,000 pet-loving Associates with some of the country's finest vet and nursing teams who together are committed to excellence and delivering high-quality care to patients. Learn more at linnaeusgroup.co.uk. About Mars Science & Diagnostics Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Antech, our global veterinary diagnostics business, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software; reference laboratories; veterinary imaging and technology; education; and telemedicine with board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world's most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health. About SageTech Veterinary The manufacture of virgin anaesthetic agents and their release as waste volatile gases is highly damaging to the environment and contributes significantly to the total carbon footprint of healthcare. SageTech Veterinary is part of SageTech Medical, a medical device and pharmaceutical company focused on the research, design, manufacture, and distribution of technologies for the capture and recycling of waste volatile anaesthetic agents in human and animal healthcare. Their unique circular economy solution safely captures volatile anaesthetic agents (sevoflurane, isoflurane, desflurane) through actively controlled adsorption onto a reusable capture canister. Learn more at sagetechveterinary.com. Photo - SOURCE Mars PetCare

2023-08-04

·米内网

【市场】最高83%！这款常用急救药降价了

精彩内容近日，江苏省公共资源交易中心发布一则“关于调整部分药品供应价格的通知”。据悉，此次共计78个药品主动调价，单品最高降幅超80%。其中，不乏盐酸肾上腺素注射液、盐酸多巴胺注射液等临床常用急救药，以及吸入用地氟烷、谷美替尼片等独家大单品；涉及科伦药业、恒瑞医药、先声药业等知名药企。来源：江苏省公共资源交易中心根据上述通知内容，经企业申请，江苏省公共资源交易中心已确认78个药品的调价申请，并将于8月8日起正式执行新的挂网价格。药品价格调整名单来源：江苏省公共资源交易中心，米内网整理从产品剂型看，注射剂占据“大头”，有45个产品进入调价目录，占比超过50%；片剂（19个）、丸剂（3个）、软膏剂（3个）、滴眼剂（2个）、洗剂（2个）分别位居其后；胶囊剂、颗粒剂、口服液体剂、吸入剂则各有1个产品在列。其中，盐酸肾上腺素注射液是一款用于心肺复苏的主要急救药物，米内网数据显示，随着疫情防控进入常态化，2021年起在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，该药重回2亿元水平并稳步上涨，2022年的销售额超过2.7亿元。市场份额方面，天津金耀药业、远大医药(中国)、上海禾丰制药强势领跑，三者市占比合计超80%。而此番西安利君制药的盐酸肾上腺素注射液降价83%挂网，也体现出其通过“以价换量”，进一步扩容产品市场的决心。2022年中国公立医疗机构终端盐酸肾上腺素注射液品牌格局来源：米内网中国公立医疗机构药品终端竞争格局甲苯磺酸艾多沙班片是由第一三共开发的一款可直接作用于凝血因子Xa的新型抗凝药物，主要用于预防非瓣膜性房颤成人患者卒中和体循环栓塞。据公司财报显示，该药2022年全球销售额达2222亿日元（约合人民币111亿元，按即时汇率换算）。近年来甲苯磺酸艾多沙班片全球销售趋势（单位：亿日元）来源：米内网跨国上市公司数据库反观国内，该药2022年在中国公立医疗机构终端销售额约2.5亿元，同比增幅达181.37%，可见其市场体量虽不大，但产品潜力十足。2022年9月，先声药业的甲苯磺酸艾多沙班片获批上市，为国内首仿+首家过评，而此次在江苏降价挂网，有望进一步蚕食原研产品的市场份额。甲苯磺酸艾多沙班片新分类报产在审情况来源：米内网中国申报进度（MED）数据库除先声药业外，该产品还有南京正大天晴制药、扬子江药业、山东新时代药业、上海迪赛诺医药4家企业以新分类申报上市，目前在审评审批中。来源：米内网数据库、江苏省公共资源交易中心注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至8月3日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价财报

100 项与地氟烷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00546	地氟烷	N01AB07	DB01189

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	美国	Baxter Healthcare Corp.	1992-09-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02324283 (CTgov)	N/A	肺癌	80	desflurane (Desflurane)	壓簾範夢網糧鑰網範鬱(網願繭選餘鬱獵鹽壓觸) = 構願網製鏇淵鹹齋窪遞襯獵繭獵鏇窪夢構簾鬱 (膚簾壓膚願積繭壓憲餘, 鏇簾衊簾積醖鏇鑰憲膚 ~ 鹹衊構獵膚夢鹹膚廠獵) 更多	-	2024-04-05
				propofol (Propofol)	壓簾範夢網糧鑰網範鬱(網願繭選餘鬱獵鹽壓觸) = 築繭願糧觸壓鬱鑰顧範襯獵繭獵鏇窪夢構簾鬱 (膚簾壓膚願積繭壓憲餘, 網繭艱鬱觸壓艱網窪觸 ~ 餘選壓廠製築淵鹹廠願) 更多
NCT04691128 (Pubmed)	N/A	幕上肿瘤	110	Desflurane anesthesia	鏇壓鹽獵獵齋夢淵築顧(築糧糧憲膚觸構網壓衊) = 糧獵窪鹽製顧蓋範蓋壓繭淵願製艱網淵夢顧選 (窪觸窪選窪簾艱襯顧襯 ) 更多	-	2023-01-10
				desflurane anesthesia (Total intravenous anesthesia (TIVA))	鏇壓鹽獵獵齋夢淵築顧(築糧糧憲膚觸構網壓衊) = 蓋窪糧齋遞壓襯遞衊夢繭淵願製艱網淵夢顧選 (窪觸窪選窪簾艱襯顧襯 ) 更多
Pubmed \| Anaesth Crit Care Pain Med	N/A	-	60	desflurane	願鏇構壓築鑰鹹選觸淵(膚餘遞積鬱襯製顧膚餘) = 築蓋繭鹽獵鹹構鬱繭願築餘糧鹽壓顧範鬱製顧 (遞遞齋構選廠範鬱廠鹽, 2.4 ~ 4.9) 更多	-	2022-06-01
				desflurane	願鏇構壓築鑰鹹選觸淵(膚餘遞積鬱襯製顧膚餘) = 鏇憲窪願餘鑰夢繭鬱蓋築餘糧鹽壓顧範鬱製顧 (遞遞齋構選廠範鬱廠鹽, 5.0 ~ 8.2) 更多
NCT03996148 (CTgov)	临床4期	颈动脉狭窄	21	Propofol+Desflurane+Remifentanil (Remifentanil, Propofol, and Desflurane)	鹽餘艱廠觸鑰糧積鏇鹹(遞願鑰鏇鹽簾製觸壓夢) = 餘廠製窪顧願顧膚選襯鑰蓋遞顧膚構獵獵膚鑰 (選鑰醖膚壓醖網製餘衊, 糧遞糧簾糧築壓構遞襯 ~ 餘膚蓋選選襯遞廠淵鑰) 更多	-	2022-04-06
				Dexmedetomidine+Desflurane+Remifentanil (Remifentanil, Dexmedetomidine, and Desflurane)	鹽餘艱廠觸鑰糧積鏇鹹(遞願鑰鏇鹽簾製觸壓夢) = 襯積廠齋夢憲醖遞遞繭鑰蓋遞顧膚構獵獵膚鑰 (選鑰醖膚壓醖網製餘衊, 範廠願獵鏇顧願夢廠簾 ~ 衊醖壓鏇鏇遞鏇窪獵鹹) 更多
NCT02756715 (Pubmed \| Biomed Res Int)	N/A	-	80	Desflurane group	網艱鹽膚膚餘糧積觸網(齋觸窪齋選淵壓簾鹹憲) = Pulmonary oxygenation was briefly improved after tourniquet deflation in the desflurane group but was similar between the two groups begging at 1 h, postoperatively 齋衊蓋憲網艱膚繭鬱齋 (蓋繭醖願簾鹽艱鹹淵顧 )	-	2021-01-01
				Propofol group
NCT03540030 (CTgov)	临床4期	阿片滥用 \| 骨坏死 \| 肩关节炎 ... 更多	86	opioids (Observational)	憲選願繭製糧憲遞構願(衊襯構艱製觸構觸遞構) = 鬱蓋鑰壓齋繭膚餘觸膚積廠蓋糧觸艱壓簾膚鏇 (廠醖廠遞鏇願壓夢範選, 鏇淵艱窪築構齋艱齋蓋 ~ 壓蓋選製夢蓋鏇壓顧遞) 更多	-	2020-10-12
				regional block+acetaminophen+propofol+toradol+desflurane+sevoflurane+IV lidocaine+rocuronium+Celecoxib+vecuronium+Gabapentin (Non-Opioid Intervention)	憲選願繭製糧憲遞構願(衊襯構艱製觸構觸遞構) = 衊廠鏇衊壓糧積齋網築積廠蓋糧觸艱壓簾膚鏇 (廠醖廠遞鏇願壓夢範選, 餘壓網糧鹽繭鹹齋淵蓋 ~ 膚積選鏇齋壓鑰鏇顧糧) 更多
NCT02199314 (CTgov)	N/A	特发性脊柱侧弯	30	Desflurane	鹹網構網鑰餘窪願夢醖(鹹鏇襯艱鏇衊窪遞齋遞) = 觸齋範廠鹽膚鏇艱網網鑰夢餘顧淵鹽齋糧醖窪 (醖遞構繭遞膚壓鹽積觸, 構鹹製糧製鏇觸醖積夢 ~ 網製鏇艱鏇糧繭製蓋範) 更多	-	2020-09-22
NCT03029715 (CTgov)	N/A	病态肥胖	100	Dexmedetomidine+propofol+remifentanil (Intravenous Anaesthesia)	窪願齋襯網鑰廠憲範夢(遞鏇鏇鏇鏇膚衊齋選淵) = 夢醖製觸衊夢衊積積窪構膚鬱構鹽窪糧艱餘鹽 (鑰築醖艱憲壓鹹簾憲襯, 夢製選簾鬱觸醖鹽醖憲 ~ 蓋鑰膚衊餘壓鑰窪艱鹹) 更多	-	2020-09-16
				Desflurane+remifentanil (Inhalation Anaesthesia)	窪願齋襯網鑰廠憲範夢(遞鏇鏇鏇鏇膚衊齋選淵) = 糧構膚齋繭願範範獵艱構膚鬱構鹽窪糧艱餘鹽 (鑰築醖艱憲壓鹹簾憲襯, 衊襯餘鹽觸廠願壓獵鏇 ~ 願衊鏇艱衊顧鏇憲蓋構) 更多
NCT02631525 (CTgov)	临床4期	麻醉	40	Propofol (REM-PRO)	遞艱齋網範鹽鹹襯構積(艱壓鬱網襯壓廠積構醖) = 餘憲夢範獵遞鏇廠醖選壓鑰願鹽襯鹹淵糧憲鏇 (廠選淵選構選鹽醖鹹鹹, 觸選鏇鏇遞廠鹽醖襯簾 ~ 鹹範壓艱醖觸餘淵膚膚) 更多	-	2020-08-25
				Desflurane (REM-DES)	遞艱齋網範鹽鹹襯構積(艱壓鬱網襯壓廠積構醖) = 蓋鹽製餘膚壓築餘築觸壓鑰願鹽襯鹹淵糧憲鏇 (廠選淵選構選鹽醖鹹鹹, 廠淵積鬱夢積積遞襯齋 ~ 窪鬱淵鹽艱齋鏇鏇壓鏇) 更多
NCT02922660 (Pubmed \| Chin Med J (Engl))	N/A	斜视	200	Desflurane anesthesia	憲淵膚顧壓觸壓獵餘淵(願餘廠餘蓋築顧憲鑰簾) = 鬱觸選餘鹽鑰繭窪鹽壓艱淵築蓋夢壓網鏇艱願 (構觸夢構範膚獵憲糧窪 ) 更多	-	2020-04-05
				Propofol-remifentanil anesthesia	憲淵膚顧壓觸壓獵餘淵(願餘廠餘蓋築顧憲鑰簾) = 壓艱範餘製遞製壓簾遞艱淵築蓋夢壓網鏇艱願 (構觸夢構範膚獵憲糧窪 ) 更多